| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 05/22/2002 | EP1206474A1 Sulfonylphenylpyrazole compounds useful as cox-2 inhibitors |
| 05/22/2002 | EP1206473A1 Isomeric fused pyrrolocarbazoles and isoindolones |
| 05/22/2002 | EP1206472A1 Oxazole and thiazole derivatives as neurotrophin production/secretion promoting agent |
| 05/22/2002 | EP1206467A1 N-heterocyclic derivatives as nos inhibitors |
| 05/22/2002 | EP1206458A1 Benzoxazine and benzothiazine derivatives and the use thereof in medicaments |
| 05/22/2002 | EP1206457A1 Biaryl-oxa(thia)zole derivatives and their use as ppars modulators |
| 05/22/2002 | EP1206448A1 Novel vitamin d analogues |
| 05/22/2002 | EP1206444A1 Compounds that inhibit tryptase activity |
| 05/22/2002 | EP1206442A1 Substituted chiral allosteric hemoglobin modifiers |
| 05/22/2002 | EP1206264A2 Compositions and methods for treating opiate intolerance |
| 05/22/2002 | EP1206262A1 Npy antagonists: spiroisoquinolinone derivatives |
| 05/22/2002 | EP1206261A2 Pharmaceutical compositions comprising clavulanic acid or derivative thereof for the treatment of behavioral diseases |
| 05/22/2002 | EP1206248A2 Controlled-release sedative-hypnotic compositions and methods related thereto |
| 05/22/2002 | EP1206233A2 Serine proteases |
| 05/22/2002 | EP1206190A1 Vaccines for the treatment of autoimmune disease |
| 05/22/2002 | EP1152776B1 Biodegradable, injectable oligomer-polymer composition |
| 05/22/2002 | EP0894093B1 Soluble tachykinin antagonists, the preparation and use thereof |
| 05/22/2002 | CN1350545A Spray drying of thrombin inhibitors |
| 05/22/2002 | CN1350538A Imiadazodiazepine derivative |
| 05/22/2002 | CN1350537A Cyclic substituted fused pyrrolocarbazoles and isoindolones |
| 05/22/2002 | CN1350536A 氨基甲酰基四氢吡啶衍生物 Carbamoyl tetrahydropyridine derivative |
| 05/22/2002 | CN1350530A 酰胺衍生物 Amide derivatives |
| 05/22/2002 | CN1350528A 4,5,6,7-tetrahydroindazole derivatives as antitumor agents |
| 05/22/2002 | CN1350519A Reversible aqueous pH Sensitive lipidizing reagents, compositions and methods of use |
| 05/22/2002 | CN1350512A Method of preparing surface-active alcohols and surface-active alcoholic ethers, products obtained by said method and their use |
| 05/22/2002 | CN1350459A Glycosaminoglycans having an average molecular weight equal to 2400 D suitable for the treatment of senile dementia |
| 05/22/2002 | CN1350457A Use of 1,2,4-triazolo [1,5-A] pyrimide in derivatives for treating migraine |
| 05/22/2002 | CN1350456A Pharmaceutical compositions comprising a pyrimidine derivative and cyclodextrin |
| 05/22/2002 | CN1349989A 4-hydroxyl-piperidine derivative |
| 05/22/2002 | CN1349816A Medicine for treating Alzheimer disease and cerebral ischemic encephalopathy and its prepn |
| 05/22/2002 | CN1085206C Benzofurazan compounds which enhance AMPA receptor activity |
| 05/22/2002 | CN1085095C Preparation method of medicine Huanshen xingnao for curing encephalomyelopathy |
| 05/21/2002 | US6392053 Process for preparing arylacetylaminothiazoles |
| 05/21/2002 | US6392045 9-azobicyclo[3.3.1] non-2-ene derivatives as cholinergic ligands at nicotinic ACH receptors |
| 05/21/2002 | US6392039 Coupling; salt formation |
| 05/21/2002 | US6392038 Seeding solution of racemic mixture; dissolving in solvent; extraction |
| 05/21/2002 | US6391922 Administering neurotransmitter |
| 05/21/2002 | US6391914 Optically active aminopentane derivatives |
| 05/21/2002 | US6391910 Opioid antagonist; analgesic |
| 05/21/2002 | US6391896 3-Tetrahydropyridin-4-yl indoles for treatment of psychotic disorders |
| 05/21/2002 | US6391893 Anticancer agents |
| 05/21/2002 | US6391892 Naphthyl pharmaceutical compounds |
| 05/21/2002 | US6391891 Bicyclic compounds as ligands for 5-HT1 receptors |
| 05/21/2002 | US6391887 3,4-Dihydroquinoline derivatives as nitrogen monoxide synthase (NOS) inhibitors |
| 05/21/2002 | US6391878 Compounds such as (4,7-dimethylbenzimidazol-5-yl)guanidine; treating nasal congestion, otitis media, asthma, pain, migraine, gastrointestinal disorder, ulcer |
| 05/21/2002 | US6391876 Reboxetine for treatment obsessive compulsive disorders and panic disorder |
| 05/21/2002 | US6391875 Pharmaceutically active morpholinol |
| 05/21/2002 | US6391873 Anxiolytic agents; anticonvulsants; therapy for sleep disorders |
| 05/21/2002 | US6391870 Dopaminergic agent |
| 05/21/2002 | US6391866 Analgesics |
| 05/21/2002 | US6391344 By administering rosemary or sage extracts; carnosic acid, carnosol |
| 05/21/2002 | US6391309 Composition made from plant matter enriched in at least two phytochemicals selected from isoflavones, lignans, saponins, sapogenins, catechins and phenolic acids; therapeutic treatment for female disorders |
| 05/21/2002 | US6391308 Method of preparing and using isoflavones for the treatment of blood related illnesses |
| 05/21/2002 | US6390821 Phosphorylation |
| 05/21/2002 | CA2330480C Controlled release formulation of divalproex sodium |
| 05/21/2002 | CA2134077C 4-imidomethyl-1-¬2'phenyl-2'oxoethyl-|piperidines as serotonin 5ht2-antagonists, their preparation and use in therapy |
| 05/20/2002 | WO2002039947A2 Carrier vectors through an epithelium with tight junctions |
| 05/16/2002 | WO2002038778A1 Differentiation-inducing substances |
| 05/16/2002 | WO2002038744A2 Proteases |
| 05/16/2002 | WO2002038730A2 Novel human potassium channel beta subunit |
| 05/16/2002 | WO2002038610A1 Process for the preparation of latent antithrombin iii |
| 05/16/2002 | WO2002038607A2 A 'bach' g protein coupled receptor polypeptide and polynucleotide encoding this receptor |
| 05/16/2002 | WO2002038601A2 Foggy |
| 05/16/2002 | WO2002038575A1 Glycerophosphoinositol derivatives as modulators of cytosolic a2 phospholipase |
| 05/16/2002 | WO2002038569A1 Imidazo-pyrimidine derivatives as ligands for gaba receptors |
| 05/16/2002 | WO2002038568A1 Imidazo-triazine derivatives as ligands for gaba receptors |
| 05/16/2002 | WO2002038561A1 Indolylmaleimide derivatives as protein kinase c inhibitors |
| 05/16/2002 | WO2002038548A1 Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists |
| 05/16/2002 | WO2002038547A1 Quinoline derivatives as nk-3 and nk-2 antagonists |
| 05/16/2002 | WO2002038208A2 Device and method for the cessation of smoking |
| 05/16/2002 | WO2002038179A1 Preventives or remedies for endoplasmic reticulum stress-associated diseases |
| 05/16/2002 | WO2002038177A2 Adjuvant combination formulations |
| 05/16/2002 | WO2002038169A1 Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2 |
| 05/16/2002 | WO2002038144A2 The use of tiagabine for treatment of diabetic neuropathy and migraine |
| 05/16/2002 | WO2002038142A2 Serotonergic compositions and methods for treatment of mild cognitive impairment |
| 05/16/2002 | WO2002038141A2 Compositions and methods for treatment of mild cognitive impairment |
| 05/16/2002 | WO2002038140A2 Therapeutic uses for ip3 receptor-mediated calcium channel modulators |
| 05/16/2002 | WO2002038129A2 Delayed-release pharmaceutical formulations containing proinsulin c-peptide |
| 05/16/2002 | WO2002038108A2 Methods of treating disorders related to apoe |
| 05/16/2002 | WO2002038035A2 Methods for inhibiting pain |
| 05/16/2002 | WO2002037927A2 Compounds and methods for promoting smoking cessation |
| 05/16/2002 | WO2002026727A3 Methods of providing and using compounds (retinoids) having activity as inhibitors of cytochrome p450rai |
| 05/16/2002 | WO2002022658A3 Muteins of the cgrp 1-7 peptide fragment and use thereof as nicotinic neuronal receptor enhancers |
| 05/16/2002 | WO2002017930A3 Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| 05/16/2002 | WO2002016356A3 Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands) |
| 05/16/2002 | WO2002010158A3 3-indolyl-4-phenyl-1h-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta |
| 05/16/2002 | WO2002004442A3 Azabicyclic compounds as inhibitors of nicotinic cholinergic receptors |
| 05/16/2002 | WO2002002090A3 Inhibitors of copper-containing amine oxidases |
| 05/16/2002 | WO2001098291A3 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders |
| 05/16/2002 | WO2001098290A3 Thiophene derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 05/16/2002 | WO2001096372A3 Zinc transporters proteins and their use in medicinal preparations |
| 05/16/2002 | WO2001083552A3 Human sez6 nucleic acids and polypeptides |
| 05/16/2002 | WO2001083547A3 Anti-inflammatory compounds and uses thereof |
| 05/16/2002 | WO2001081319A3 Ultrashort acting hypnotic barbiturates |
| 05/16/2002 | WO2001074857A3 Methods and compositions for modulating integrin-mediated cell-cell interactions |
| 05/16/2002 | WO2001074364A3 A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease |
| 05/16/2002 | WO2001070663A3 Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors |
| 05/16/2002 | WO2001070662A3 2,4-pentadienoic acid derivatives having selective activity for retinoid x (rxr) receptors |
| 05/16/2002 | WO2001069261A3 Proteins, genes and their use for diagnosis and treatment of vascular dementia |
| 05/16/2002 | WO2001068678A3 Peptides that selectively bind to expanded polyglutamine repeat domains and methods of use thereof |